RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Clearside Biomedical Stock

Clearside Biomedical EBIT 2025

Clearside Biomedical EBIT

-24.77 M USD

Ticker

CLSD

ISIN

US1850631045

WKN

A2ALP6

In 2025, Clearside Biomedical's EBIT was -24.77 M USD, a -14.24% increase from the -28.88 M USD EBIT recorded in the previous year.

The Clearside Biomedical EBIT history

YEAREBIT (undefined USD)
2030e-
2029e23.49
2028e-29.95
2027e-49.18
2026e-33.84
2025e-24.77
2024-28.88
2023-24.84
2022-30.28
2021-0.62
2020-17.94
2019-30.3
2018-82.95
2017-58.41
2016-25.2
2015-17.32
2014-9.82
2013-7.24

Clearside Biomedical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Clearside Biomedical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Clearside Biomedical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Clearside Biomedical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Clearside Biomedical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Clearside Biomedical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Clearside Biomedical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Clearside Biomedical’s growth potential.

Clearside Biomedical Revenue, EBIT and net profit per share

DateClearside Biomedical RevenueClearside Biomedical EBITClearside Biomedical Net Income
2030e142.04 M undefined0 undefined45.17 M undefined
2029e71.31 M undefined23.49 M undefined30.11 M undefined
2028e14.44 M undefined-29.95 M undefined-11.29 M undefined
2027e14.82 M undefined-49.18 M undefined-37.64 M undefined
2026e3.5 M undefined-33.84 M undefined-45.96 M undefined
2025e2.97 M undefined-24.77 M undefined-30.65 M undefined
20241.66 M undefined-28.88 M undefined-34.35 M undefined
20238.23 M undefined-24.84 M undefined-32.49 M undefined
20221.33 M undefined-30.28 M undefined-32.95 M undefined
202129.58 M undefined-620,000 undefined380,000 undefined
20207.89 M undefined-17.94 M undefined-18.21 M undefined
20192.17 M undefined-30.3 M undefined-30.77 M undefined
201830,000 undefined-82.95 M undefined-82.82 M undefined
2017350,000 undefined-58.41 M undefined-58.98 M undefined
2016520,000 undefined-25.2 M undefined-25.88 M undefined
20150 undefined-17.32 M undefined-17.64 M undefined
20140 undefined-9.82 M undefined-10.19 M undefined
20130 undefined-7.24 M undefined-7.25 M undefined

Clearside Biomedical stock margins

The Clearside Biomedical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Clearside Biomedical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Clearside Biomedical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Clearside Biomedical's sales revenue. A higher gross margin percentage indicates that the Clearside Biomedical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Clearside Biomedical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Clearside Biomedical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Clearside Biomedical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Clearside Biomedical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Clearside Biomedical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Clearside Biomedical Margin History

Clearside Biomedical Gross marginClearside Biomedical Profit marginClearside Biomedical EBIT marginClearside Biomedical Profit margin
2030e91.05 %0 %31.8 %
2029e91.05 %32.94 %42.23 %
2028e91.05 %-207.48 %-78.23 %
2027e91.05 %-331.87 %-254 %
2026e91.05 %-967.91 %-1,314.74 %
2025e91.05 %-834.56 %-1,032.66 %
202491.05 %-1,735.7 %-2,064.42 %
202395.68 %-302.02 %-394.91 %
202284.21 %-2,276.69 %-2,477.44 %
202191.05 %-2.1 %1.28 %
202091.05 %-227.38 %-230.8 %
201991.05 %-1,396.31 %-1,417.97 %
201891.05 %-276,500 %-276,066.67 %
201791.05 %-16,688.57 %-16,851.43 %
201691.05 %-4,846.15 %-4,976.92 %
201591.05 %0 %0 %
201491.05 %0 %0 %
201391.05 %0 %0 %

Clearside Biomedical Aktienanalyse

What does Clearside Biomedical do?

Clearside Biomedical Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of eye diseases and other medical conditions. The company was founded in 2011 by an experienced team of researchers and developers and is based in Alpharetta, Georgia. Clearside Biomedical Inc's history can be traced back to the groundbreaking research of Professor Henry Edelhauser, a renowned ophthalmologist and leading expert in the field of ophthalmology. Professor Edelhauser had the idea that by injecting drugs directly into the eye, specifically into the back part of the eye, more effective treatment could be achieved. Together with his team, he developed an innovative method for injecting drugs into the vitreous humor of the eye, which Clearside Biomedical Inc uses in its work. The business model of Clearside Biomedical Inc is based on the development and commercialization of therapies that rely on the intravitreal injection of drugs into the eye. The goal is to deliver drugs more effectively and precisely to the site of action, thus increasing the effectiveness of the treatment. The company focuses on the treatment of diseases of the posterior segment of the eye, such as age-related macular degeneration, diabetic retinopathy, or retinal vein occlusions. The various divisions of Clearside Biomedical Inc include research and development, clinical trials, manufacturing and marketing of therapies, as well as marketing and sales. The company places great importance on collaboration with leading scientists and regulatory bodies to ensure the effectiveness and safety of their products. Clearside Biomedical Inc's products include various innovative therapies for intravitreal injection, such as the drug Zuprata. Zuprata is a steroid specifically developed for the treatment of diseases of the posterior segment of the eye and has high efficacy. The drug is injected directly into the vitreous humor of the eye and has the advantage of being longer-lasting than other steroids. Another product of Clearside Biomedical Inc is the CLS-TA implant. The implant is based on an innovative technology that allows for continuous delivery of drugs over a longer period of time. The implant is directly implanted into the posterior part of the eye and can help increase the efficacy of drugs and reduce the number of necessary injections. Clearside Biomedical Inc has made significant progress in recent years and has successfully conducted several clinical trials. In 2019, the company received approval from the US Food and Drug Administration (FDA) for the marketing of Zuprata for the treatment of macular edema associated with uveitis. Overall, Clearside Biomedical Inc has a promising future. The company relies on innovative technologies and close collaboration with leading experts in the field of ophthalmology to develop new therapies and provide patients with better treatment options. Clearside Biomedical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Clearside Biomedical's EBIT

Clearside Biomedical's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Clearside Biomedical's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Clearside Biomedical's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Clearside Biomedical’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Clearside Biomedical stock

How much did Clearside Biomedical achieve in EBIT for the current year?

In the current year, Clearside Biomedical has achieved an EBIT of -24.77 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Clearside Biomedical.

How has the EBIT of Clearside Biomedical developed in recent years?

The EBIT of Clearside Biomedical has increased by -14.238% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Clearside Biomedical?

The EBIT of Clearside Biomedical is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Clearside Biomedical pay?

Over the past 12 months, Clearside Biomedical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Clearside Biomedical is expected to pay a dividend of 0 USD.

What is the dividend yield of Clearside Biomedical?

The current dividend yield of Clearside Biomedical is .

When does Clearside Biomedical pay dividends?

Clearside Biomedical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Clearside Biomedical?

Clearside Biomedical paid dividends every year for the past 0 years.

What is the dividend of Clearside Biomedical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Clearside Biomedical located?

Clearside Biomedical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Clearside Biomedical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Clearside Biomedical from 8/18/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/18/2025.

When did Clearside Biomedical pay the last dividend?

The last dividend was paid out on 8/18/2025.

What was the dividend of Clearside Biomedical in the year 2024?

In the year 2024, Clearside Biomedical distributed 0 USD as dividends.

In which currency does Clearside Biomedical pay out the dividend?

The dividends of Clearside Biomedical are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Clearside Biomedical

Our stock analysis for Clearside Biomedical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Clearside Biomedical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.